MX2023003129A - Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). - Google Patents
Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).Info
- Publication number
- MX2023003129A MX2023003129A MX2023003129A MX2023003129A MX2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A
- Authority
- MX
- Mexico
- Prior art keywords
- adh1
- type
- autosomal dominant
- triphenyl
- treatment
- Prior art date
Links
- 201000003979 autosomal dominant hypocalcemia 1 Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 title 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 title 1
- 101100001031 Acetobacter aceti adhA gene Proteins 0.000 title 1
- 101150021974 Adh1 gene Proteins 0.000 title 1
- 230000001126 calcilytic effect Effects 0.000 title 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063080165P | 2020-09-18 | 2020-09-18 | |
| US202163159397P | 2021-03-10 | 2021-03-10 | |
| PCT/US2021/050677 WO2022060987A1 (en) | 2020-09-18 | 2021-09-16 | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003129A true MX2023003129A (es) | 2023-08-04 |
Family
ID=78087574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003129A MX2023003129A (es) | 2020-09-18 | 2021-09-16 | Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220087961A1 (https=) |
| EP (1) | EP4213829A1 (https=) |
| JP (1) | JP2023542932A (https=) |
| KR (1) | KR20230112609A (https=) |
| AU (1) | AU2021343475A1 (https=) |
| CA (1) | CA3192684A1 (https=) |
| IL (1) | IL301409A (https=) |
| MX (1) | MX2023003129A (https=) |
| TW (1) | TW202227046A (https=) |
| WO (1) | WO2022060987A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230106582A (ko) | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
| EP4698162A1 (en) * | 2023-04-21 | 2026-02-25 | Calcilytix Therapeutics, Inc. | Treatment of hypoparathyroidism using triphenyl calcilytic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407097A (pt) * | 2003-04-23 | 2006-01-24 | Japan Tobacco Inc | Antagonista do casr |
| KR20230106582A (ko) * | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
-
2021
- 2021-09-16 AU AU2021343475A patent/AU2021343475A1/en active Pending
- 2021-09-16 JP JP2023518198A patent/JP2023542932A/ja active Pending
- 2021-09-16 CA CA3192684A patent/CA3192684A1/en active Pending
- 2021-09-16 WO PCT/US2021/050677 patent/WO2022060987A1/en not_active Ceased
- 2021-09-16 US US17/477,198 patent/US20220087961A1/en active Pending
- 2021-09-16 MX MX2023003129A patent/MX2023003129A/es unknown
- 2021-09-16 EP EP21790717.9A patent/EP4213829A1/en active Pending
- 2021-09-16 IL IL301409A patent/IL301409A/en unknown
- 2021-09-16 KR KR1020237012476A patent/KR20230112609A/ko active Pending
- 2021-09-17 TW TW110134985A patent/TW202227046A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542932A (ja) | 2023-10-12 |
| KR20230112609A (ko) | 2023-07-27 |
| TW202227046A (zh) | 2022-07-16 |
| WO2022060987A1 (en) | 2022-03-24 |
| IL301409A (en) | 2023-05-01 |
| EP4213829A1 (en) | 2023-07-26 |
| AU2021343475A9 (en) | 2024-05-02 |
| US20220087961A1 (en) | 2022-03-24 |
| CA3192684A1 (en) | 2022-03-24 |
| AU2021343475A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003129A (es) | Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). | |
| CR20250500A (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| MX2022003018A (es) | Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. | |
| MX2023014307A (es) | Inhibidores de proteasa como antivirales. | |
| BR112015021982A2 (pt) | compostos e seus usos para a modulação de hemoglobina | |
| MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
| MX2024011403A (es) | Tratamiento con mirdametinib. | |
| MX2023012840A (es) | Derivados de ftalazinona como inhibidores del inflamasoma nlrp3. | |
| WO2023107574A3 (en) | Lipid-based compositions and methods thereof | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| WO2023147297A3 (en) | Combination therapy for treating abnormal cell growth | |
| MX2023013972A (es) | Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos. | |
| PE20221768A1 (es) | Inhibidores de egfr | |
| MX2024012882A (es) | Compuestos de liberacion de gamma-hidroxibutirato y procesos para fabricar y usar los mismos | |
| PH12022552495A1 (en) | Oxazolidinone compound and methods of use thereof as an antibacterial agent | |
| JOP20250057A1 (ar) | مركبات لعلاج السرطان | |
| MX2024013787A (es) | Inhibidores de menina-mll para el tratamiento de cáncer. | |
| MX2026001837A (es) | Compuestos que contienen ciclobutilo | |
| MX2023009600A (es) | Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias. | |
| MX2024010480A (es) | Uso de inhibidor de captacion triple para el tratamiento de la depresion atipica. | |
| Fleisher et al. | 1, 1'-Trimethylene bis (4-formylpyridinium bromide) dioxime (TMB-4) and 2-pyridine aldoxime methiodide (2-PAM) as adjuvants to atropine in the treatment of anticholinesterase poisoning | |
| AR129002A1 (es) | Inhibidores de egfr | |
| WO2022081610A8 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
| MX2023004435A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis. | |
| MX2023009620A (es) | Metodos terapeuticos. |